Previous reports identified high incidence of the truncating PPM1D mutations in patients with therapy-induced AML [28, 29] and established the role of PPM1D as a driver in CH, but whether these mutations can contribute to malignant transformation per se remained elusive. This evidence concerns the gene PPM1D and cyclic hematopoiesis.